These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 26718446)

  • 21. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens.
    Sugarman EA; Nagan N; Zhu H; Akmaev VR; Zhou Z; Rohlfs EM; Flynn K; Hendrickson BC; Scholl T; Sirko-Osadsa DA; Allitto BA
    Eur J Hum Genet; 2012 Jan; 20(1):27-32. PubMed ID: 21811307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preconception and prenatal screening for cystic fibrosis.
    Baskin LB; Wians FH; Elder F
    MLO Med Lab Obs; 2002 Oct; 34(10):8-12; quiz 14, 16. PubMed ID: 12385171
    [No Abstract]   [Full Text] [Related]  

  • 23. Targeted carrier screening for four recessive disorders: high detection rate within a founder population.
    Mathijssen IB; Henneman L; van Eeten-Nijman JM; Lakeman P; Ottenheim CP; Redeker EJ; Ottenhof W; Meijers-Heijboer H; van Maarle MC
    Eur J Med Genet; 2015 Mar; 58(3):123-8. PubMed ID: 25641760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expanded Carrier Screening.
    Gregg AR
    Obstet Gynecol Clin North Am; 2018 Mar; 45(1):103-112. PubMed ID: 29428278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Introduction to molecular cystic fibrosis testing.
    Uphoff TS; Highsmith WE
    Clin Lab Sci; 2006; 19(1):24-31. PubMed ID: 16617555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Offering preconceptional cystic fibrosis carrier couple screening in the absence of established preconceptional care services.
    Henneman L; Bramsen I; van Kempen L; van Acker MB; Pals G; van der Horst HE; Adèr HJ; van der Ploeg HM; ten Kate LP
    Community Genet; 2003; 6(1):5-13. PubMed ID: 12748433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Preconceptional carrier screening should not be delayed].
    Cornel MC; Lakeman P; Dondorp W
    Ned Tijdschr Geneeskd; 2011; 155():A3205. PubMed ID: 21504638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carrier testing for spinal muscular atrophy.
    Gitlin JM; Fischbeck K; Crawford TO; Cwik V; Fleischman A; Gonye K; Heine D; Hobby K; Kaufmann P; Keiles S; MacKenzie A; Musci T; Prior T; Lloyd-Puryear M; Sugarman EA; Terry SF; Urv T; Wang C; Watson M; Yaron Y; Frosst P; Howell RR
    Genet Med; 2010 Oct; 12(10):621-2. PubMed ID: 20808230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population screening and cascade testing for carriers of SMA.
    Smith M; Calabro V; Chong B; Gardiner N; Cowie S; du Sart D
    Eur J Hum Genet; 2007 Jul; 15(7):759-66. PubMed ID: 17392705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expanded carrier screening for preconception reproductive risk assessment: Prevalence of carrier status in a Mexican population.
    Hernandez-Nieto C; Alkon-Meadows T; Lee J; Cacchione T; Iyune-Cojab E; Garza-Galvan M; Luna-Rojas M; Copperman AB; Sandler B
    Prenat Diagn; 2020 Apr; 40(5):635-643. PubMed ID: 32003480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cystic fibrosis: selecting the prenatal screening strategy of choice.
    Wald NJ; Morris JK; Rodeck CH; Haddow JE; Palomaki GE
    Prenat Diagn; 2003 Jun; 23(6):474-83. PubMed ID: 12813761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Use of Expanded Carrier Screening in Reproductive Medicine: Scientific Impact Paper No. 74.
    Elson J; Drakeley A; Achilli C; Canham N; Kulke C;
    BJOG; 2024 Sep; 131(10):e81-e85. PubMed ID: 38839259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population-based carrier screening for cystic fibrosis in Victoria: the first three years experience.
    Massie J; Petrou V; Forbes R; Curnow L; Ioannou L; Dusart D; Bankier A; Delatycki M
    Aust N Z J Obstet Gynaecol; 2009 Oct; 49(5):484-9. PubMed ID: 19780730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carrier testing for Ashkenazi Jewish disorders in the prenatal setting: navigating the genetic maze.
    Ferreira JC; Schreiber-Agus N; Carter SM; Klugman S; Gregg AR; Gross SJ
    Am J Obstet Gynecol; 2014 Sep; 211(3):197-204. PubMed ID: 24508465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How should preconceptional cystic fibrosis carrier screening be provided? Opinions of potential providers and the target population.
    Poppelaars FA; Henneman L; Adèr HJ; Cornel MC; Hermens RP; van der Wal G; ten Kate LP
    Community Genet; 2003; 6(3):157-65. PubMed ID: 15237200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation and characterization of a high-resolution melting analysis kit for rapid carrier-screening test of spinal muscular atrophy.
    Wang KC; Chang CC; Chang YF; Wang SH; Chiang CK; Tsai CP
    J Neurogenet; 2015; 29(2-3):113-6. PubMed ID: 25895942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carrier testing for autosomal-recessive disorders.
    Vallance H; Ford J
    Crit Rev Clin Lab Sci; 2003 Aug; 40(4):473-97. PubMed ID: 14582604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening for cystic fibrosis carrier state.
    Mennuti MT; Thomson E; Press N
    Obstet Gynecol; 1999 Mar; 93(3):456-61. PubMed ID: 10075000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Finding Middle Ground in Constructing a Clinically Useful Expanded Carrier Screening Panel.
    Stevens B; Krstic N; Jones M; Murphy L; Hoskovec J
    Obstet Gynecol; 2017 Aug; 130(2):279-284. PubMed ID: 28697118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do people from the Jewish community prefer ancestry-based or pan-ethnic expanded carrier screening?
    Holtkamp KC; van Maarle MC; Schouten MJ; Dondorp WJ; Lakeman P; Henneman L
    Eur J Hum Genet; 2016 Feb; 24(2):171-7. PubMed ID: 25966636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.